YouTube video by DiabolicHipHop

View abstract Objective:We aimed to evaluate the impact of transitioning from a conventional antimicrobial stewardship team (AST) to an interdisciplinary infectious disease support team (IDST) on patient mortality.Design:Single-center retrospective cohort study.Setting:Yamanashi Prefectural Central Hospital.Patients:We included patients with bacteremia during the AST and IDST periods.Methods:We implemented an interdisciplinary IDST that provided comprehensive support beyond antimicrobial selection and treatment. We compared 28-day mortality outcomes in hospitalized patients with bacteremia during the AST-only period (April 2021–March 2022) and the IDST-intervention period (April 2022–March 2023). Cox proportional hazards modeling was used to assess 28-day mortality; multivariable logistic regression served as a prespecified sensitivity analysis. Between-group differences were tested using two-sided tests (P < .05), and 95% confidence intervals (CIs) were reported.Results:Among the 854 patients (413 in the AST group and 441 in the IDST group), AST interventions did not significantly decrease 28-day mortality compared with no-intervention cases (20.8% vs 23.3%, P = .630). However, intervention by the IDST significantly reduced 28-day mortality compared with the no-IDST group (16.1% vs 25.2%, P = .019). In the multivariate Cox proportional hazards model, IDST interventions remained independently associated with a reduced 28-day mortality (hazard ratio, 0.518; 95% CI, 0.325–0.826; P = .006).Conclusions:Transitioning from an AST to an interdisciplinary IDST model was associated with lower 28-day mortality in bacteremia cases, possibly due to sustained diagnostic and therapeutic interventions. Our findings support stewardship as a team-based process and may significantly impact patient outcomes by maintaining involvement until treatment completion and clinical stabilization.

How fast does ampicillin reach a therapeutic blood concentration? 💊⏱️ Ampicillin is a beta-lactam

Xerostomia (Dry Mouth Disease) Therapeutics Market is reaching at a CAGR of 5.80 %, Expected to Grow from USD 3.31 Billion to USD 6.16 Billion During 2025 - 2035.

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Market growth is projected to reach USD 30.34 Billion, at a 11.71% CAGR by driving industry size, share, top company analysis, segments research, trend...

Breakthrough Therapy BT Designation Market growth is projected to reach USD 26.41 Billion, at a 9.16% CAGR by driving industry size, share, top company analysis, segments research, trends and forecast...

Lupin Market share is projected to reach USD 1.65 Billion By 2035, at a 4.32 % CAGR by driving industry size, top company analysis, segments research, trends and forecast report 2025 to 2035 | MRFR

Soft Mist Inhalers Market is projected to register a CAGR of 7% to reach USD 5.89 Billion by the end of 2035, Global Soft Mist Inhalers Market Type, Application | Soft Mist Inhalers Industry

Ear Infection Treatment Market share register 4.43 Billion USD in 2024, projected to grow 3.10% CAGR to reach USD 6.20 Billion during the forecast period 2025 - 2035.